.jpg?format=webp&quality=80&width=3840)
Pioglitazone is a potent insulin‐sensitizing drug with anti‐atherosclerotic properties, but adverse effects have limited its use. Therefore, the study assessed the benefits and risks of lower versus higher doses of pioglitazone taken by participants in the Insulin Resistance Intervention in Stroke Trial. Lower doses of pioglitazone appear to confer much benefit with less adverse effects than the total dose. However, further study is needed to confirm these findings so that clinicians may optimize this secondary prevention strategy's dosing in patients with stroke.
Like
Save
Share